Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2019 | Update on CLL research at Memorial Sloan Kettering

Anthony Mato • 1 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, discusses the priorities of chronic lymphocytic leykemia (CLL) research at his institute currently. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Anthony Mato

The importance of genomic testing in CLL prognosis
1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
Time-limited vs continuous therapy in CLL treatment
1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
Updates on non-covalent BTK inhibitors and their place in CLL treatment
2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
Pirtobrutinib resistance in CLL: early findings
1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Anthony Mato • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Anthony Mato • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Anthony Mato • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Anthony Mato • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals